BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17362052)

  • 1. Rivastigmine in Parkinson's disease dementia: profile report.
    Siddiqui MA; Wagstaff AJ
    Drugs Aging; 2007; 24(3):255-9. PubMed ID: 17362052
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivastigmine for dementia associated with Parkinson's disease.
    Harada CN; Shega JW; Sachs GA
    N Engl J Med; 2005 Mar; 352(13):1387; author reply 1387. PubMed ID: 15800242
    [No Abstract]   [Full Text] [Related]  

  • 3. Rivastigmine in Parkinson's disease dementia.
    Chitnis S; Rao J
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):941-55. PubMed ID: 19619073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients.
    Barone P; Burn DJ; van Laar T; Hsu C; Poewe W; Lane RM
    Mov Disord; 2008 Aug; 23(11):1532-40. PubMed ID: 18581467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia.
    Schmitt FA; Farlow MR; Meng X; Tekin S; Olin JT
    CNS Neurosci Ther; 2010 Dec; 16(6):330-6. PubMed ID: 20950329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivastigmine for dementia associated with Parkinson's disease.
    Morgan J; Sethi KD
    Curr Neurol Neurosci Rep; 2005 Jul; 5(4):263-5. PubMed ID: 15987609
    [No Abstract]   [Full Text] [Related]  

  • 7. First treatment for dementia of Parkinson's disease.
    FDA Consum; 2006; 40(5):5. PubMed ID: 17328100
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study.
    Emre M; Poewe W; De Deyn PP; Barone P; Kulisevsky J; Pourcher E; van Laar T; Storch A; Micheli F; Burn D; Durif F; Pahwa R; Callegari F; Tenenbaum N; Strohmaier C
    Clin Neuropharmacol; 2014; 37(1):9-16. PubMed ID: 24434526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease.
    Dujardin K; Devos D; Duhem S; Destée A; Marié RM; Durif F; Lacomblez L; Touchon J; Pollak P; Péré JJ
    J Neurol; 2006 Sep; 253(9):1154-9. PubMed ID: 16998649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension.
    Oertel W; Poewe W; Wolters E; De Deyn PP; Emre M; Kirsch C; Hsu C; Tekin S; Lane R
    Drug Saf; 2008; 31(1):79-94. PubMed ID: 18095748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lewy body dementia and Parkinson disease dementia].
    Meyniel C; Damier P
    Presse Med; 2007 Oct; 36(10 Pt 2):1485-90. PubMed ID: 17572053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.
    Wesnes K
    Drugs Today (Barc); 2007 Jun; 43(6):349-59. PubMed ID: 17612707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivastigmine: in Parkinson's disease dementia.
    Siddiqui MA; Wagstaff AJ
    CNS Drugs; 2006; 20(9):739-47; discussion 748-50. PubMed ID: 16953649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivastigmine for dementia associated with Parkinson's disease.
    Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
    N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease dementia--a first step?
    Press DZ
    N Engl J Med; 2004 Dec; 351(24):2547-9. PubMed ID: 15590960
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of degenerative dementia disorders--who should be treated?].
    Hasselbalch SG; Kampmann JP
    Ugeskr Laeger; 2009 Mar; 171(10):802-5. PubMed ID: 19265606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients.
    Fogelson N; Kogan E; Korczyn AD; Giladi N; Shabtai H; Neufeld MY
    Acta Neurol Scand; 2003 Apr; 107(4):252-5. PubMed ID: 12675697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
    Bullock R; Cameron A
    Curr Med Res Opin; 2002; 18(5):258-64. PubMed ID: 12240787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial.
    Devos D; Moreau C; Maltête D; Lefaucheur R; Kreisler A; Eusebio A; Defer G; Ouk T; Azulay JP; Krystkowiak P; Witjas T; Delliaux M; Destée A; Duhamel A; Bordet R; Defebvre L; Dujardin K
    J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):668-74. PubMed ID: 24218528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia.
    Gurevich TY; Shabtai H; Korczyn AD; Simon ES; Giladi N
    Mov Disord; 2006 Oct; 21(10):1663-6. PubMed ID: 16941467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.